Abstract
Introduction: Elevated plasma levels of osteoprotegerin (OPG), a secreted cytokine receptor, might be associated with increased cardiovascular (CV) risk. Methods: We measured plasma OPG levels obtained on admission and at 1 month in a pre-defined subset of patients with acute coronary syndromes (ACS) randomized to 6 - 12 months treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial (NCT00391872) . OPG was determined by enzyme immuno-assay. Rates of CV outcomes and major bleeding were presented by baseline OPG quartile groups. The multivariable associations of OPG levels (log transformed) with the composite endpoint of CV death, non-procedural spontaneous myocardial infarction (sMI) or stroke, and with non-CABG major bleeding were assessed with Cox proportional hazards models. Five adjusted models, with co-variates and incremental addition of log transformed biomarkers, were used: 1/ randomized treatment and clinical risk factors (including: age, gender and, hypertension e.g.) 2/ CRP and white blood cell count (WBC), 3/ cystatin C, 4/ hs-Troponin T and NT-proBNP and 5/ growth differentiation factor (GDF)-15. Results: OPG levels were available in 5,135 (28%) patients at baseline, with a median (interquartile interval) of 2.7 (2.0 - 3.6) ng/mL. Event rates of the composite endpoint per increasing quartile group were; 5.2%, 7.5%, 9.2% and 11.9%; and for non-CABG major bleeding: 2.4%, 2.2%, 3.8% and 7.2%. OPG levels at 1 month (n= 3,668), in patients free from any outcome event, were likewise independently associated with bleeding during follow up (n=69); with an adjusted HR of 1.43 (1.04-1.96). There was no interaction between admission OPG levels and randomized treatment. Conclusion: In multivariable analysis, osteoprotegerin was a strong and independent marker of major bleeding but not of ischemic CV events. Thus, OPG seems to provide important independent information on bleeding risk in patients with ACS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.